Han Junwen, Li Li, Zhang Chen, Huang Qianqian, Wang Shanglong, Li Wenyu, Zong Jiancheng, Li Lijie, Zhao Zhen, Zhang Zengliang, Liu Zimin, Wang Qi, Shi Yuanyuan
College of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Chenland Nutritionals, Inc., Irvine, CA, United States.
Front Pharmacol. 2022 Feb 4;12:772944. doi: 10.3389/fphar.2021.772944. eCollection 2021.
Osteoporosis is one of the most common diseases in the world which resulted in heavy socioeconomic burden and a public health threat. Glucocorticoid-induced osteoporosis (GIO) is the most common secondary reason of osteoporosis. Therapeutic strategies using traditional Chinese medicine are under investigation for osteoporosis, with efforts to improve efficacy and clarify the mechanism. The combination of Eucommia, Cuscuta, and Drynaria is widely used in traditional Chinese decoction for osteoporosis treatment, but the experimental efficacy and mechanism are still unclear. Administration of E.C.D. extracts (Eucommia, Cuscuta, and Drynaria) in experimental GIO rats resulted in decreased urinal calcium, phosphorus loss, and decreased expression of RANKL, CTX in serum, increased serum calcium, phosphorus, and OPG level. E.C.D. extracts also improved bone density, structural integrity, and biomechanical function in experimental GIO rats. These finding were associated with E.C.D. extracts' treatment efficacy to GIO . The balance between osteoclast and osteoblast activity is essential for bone remodeling and bone related disease. The E.C.D. extracts inhibited Raw 264.7 cell differentiation to osteoclast . On the other hand, it promoted OPG expression of bone marrow mesenchymal stromal cells (MSCs) which can suppress the osteoclast genesis. E.C.D. extracts also increased the Wnt1 and Runx2 expression which are related to osteoblast formation. It also regulated the paracrine effect of MSC to inhibit osteoclast differentiation. The analysis of HPLC and comprehensive pharmacology identified the constituents of E.C.D. extracts and the potential osteoporosis-related targets mediated by E.C.D. extracts. The KEGG enrichment analysis suggested that PI3K/Akt pathway may be involved in the regulation osteoclast genesis by E.C.D. extracts and the result of Western blot of assays proved it. Collectively, these data demonstrate E.C.D. extracts can inhibit osteoclast differentiation to foster experimental osteoporosis both and and it may exert the function of inhibiting osteoclast differentiation through PI3K/Akt pathway.
骨质疏松症是世界上最常见的疾病之一,会导致沉重的社会经济负担并构成公共卫生威胁。糖皮质激素性骨质疏松症(GIO)是骨质疏松症最常见的继发性原因。治疗骨质疏松症的中医策略正在研究中,致力于提高疗效并阐明其机制。杜仲、菟丝子和骨碎补的组合在治疗骨质疏松症的传统中药汤剂中广泛使用,但其实验疗效和机制仍不清楚。给实验性GIO大鼠服用杜仲、菟丝子和骨碎补提取物(E.C.D.提取物)可减少尿钙、磷流失,降低血清中RANKL、CTX的表达,提高血清钙、磷和OPG水平。E.C.D.提取物还改善了实验性GIO大鼠的骨密度、结构完整性和生物力学功能。这些发现与E.C.D.提取物对GIO的治疗效果相关。破骨细胞与成骨细胞活性之间的平衡对于骨重塑和骨相关疾病至关重要。E.C.D.提取物抑制Raw 264.7细胞向破骨细胞分化。另一方面,它促进骨髓间充质基质细胞(MSCs)的OPG表达,从而抑制破骨细胞生成。E.C.D.提取物还增加了与成骨细胞形成相关的Wnt1和Runx2表达。它还调节MSCs的旁分泌作用以抑制破骨细胞分化。HPLC分析和综合药理学鉴定了E.C.D.提取物的成分以及E.C.D.提取物介导的潜在骨质疏松症相关靶点。KEGG富集分析表明PI3K/Akt通路可能参与E.C.D.提取物对破骨细胞生成的调节,实验的蛋白质免疫印迹结果证实了这一点。总体而言,这些数据表明E.C.D.提取物可以抑制破骨细胞分化以改善实验性骨质疏松症,并且它可能通过PI3K/Akt通路发挥抑制破骨细胞分化的作用。